Sinecatechins and imiquimod as proactive sequential therapy of external genital and perianal warts in adults

Abstract

This review about the proactive sequential therapy (PST) of external genital and perianal warts (EGW) is based on the most current available clinical literature and on the broad clinical experience of a group of international experts, physicians who are well versed in the treatment of human papillomavirus-associated diseases. It provides a practical guide for the treatment of EGW, including epidemiology, etiology, clinical appearance, and diagnostic procedures for these viral infections. Furthermore, the treatment goals and current treatment options, elucidating provider- and patient-applied therapies, and the parameters driving treatment decisions are summarized. Specifically, the mode of action of the topical treatments sinecatechins and imiquimod, as well as the PST for EGW to achieve rapid and sustained clearance is discussed. The group of experts has developed a treatment algorithm giving healthcare providers a practical tool for the treatment of EGW which is very valuable in the presence of many different treatment options.

Keywords

HPV condyloma anogenital warts sinecatechins imiquimod

Get full access to this article

View all access options for this article.

References

Trottier

Franco

. The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24: S1–15.

World Health Organization. Human papillomavirus (HPV) and cervical cancer, http://www.who.int/mediacentre/factsheets/fs380/en/ (2016, accessed 14 November 2016).

Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR 2015; 64: 1–140. http://www.cdc.gov/std/tg2015/tg-2015-print.pdf (accessed 16 March 2016).

Hawkins

Winder

Ball

et al.

Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata. Virol J 2013; 10: 137–137.

Ryndock

Meyers

. A risk for non-sexual transmission of human papillomavirus? Expert Rev Anti Infect Ther 2014; 12: 1165–1170.

Liu

Rashid

Nyitray

. Penises not required: a systematic review of the potential for human papillomavirus horizontal transmission that is non-sexual or does not include penile penetration. Sex Health 2016; 13: 10–21.

Bergeron

Ferenczy

Richart

. Underwear: contamination by human papillomaviruses. Am J Obstet Gynecol 1990; 162: 25–29.

Ferenczy

Bergeron

Richart

. Human papillomavirus DNA in fomites on objects used for the management of patients with genital human papillomavirus infections. Obstet Gynecol 1989; 74: 950–954.

Brady

Byington

Davies

et al.

HPV vaccine recommendation, Committee on Infectious Diseases. Pediatrics 2012; 129: 602–605.

10.

Raymakers

AJN

et al.

Economic and humanistic burden of external genital warts. Pharmacoeconomics 2012; 30: 1–16.

11.

Stockfleth

Meyer

. Sinecatechins (Polyphenon E) ointment for treatment of external genital warts and possible future indications. Expert Opin Biol Ther 2014; 14: 1033–1043.

12.

Lacey

CJN

Woodhall

Wikstrom

et al.

2012 European guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol 2013; 27: e263–e270.

13.

Woodhall

Ramsey

Cai

et al.

Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008; 84: 161–166.

14.

World Health Organization. Factsheet Sexually transmitted infections 2016, http://www.who.int/mediacentre/factsheets/fs110/en/ (2016, accessed 30 January 2017).

15.

UK National Guidelines on the Management of Anogenital Warts, 2015. BASHH Clinical Effectiveness Group (lead author for BASSH CEG: Lazaro N), https://www.bashhguidelines.org/media/1075/uk-national-guideline-on-warts-2015-final.pdf (accessed 21 May 2017).

16.

Dinh

Sternberg

Dunne

et al.

Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999–2004. Sex Transm Dis 2008; 35: 357–360.

17.

European Centre for Disease Prevention and Control. Sexually transmitted infections in Europe 2013. Stockholm: ECDC, http://ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1373 (2015, accessed 20 August 2016).

18.

Public Health England, Health Protection Report Vol. 10, Nr 22 first published 5 July 2016, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/559993/hpr2216_stis_CRRCTD4.pdf (accessed 21 May 2017).

19.

Patel

Wagner

Singhal

et al.

Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013; 13: 39–39.

20.

Nguyen

Ramirez-Fort

Rady

. The biology of human papillomaviruses. Curr Probl Dermatol 2014; 45: 19–32.

21.

Kaderli

Schnueringer

Bruegger

. The impact of smoking on HPV infection and the development of anogenital warts. Int J Colorectal Dis 2014; 29: 899–908.

22.

Von Krogh

Lacey

CJN

Gross

et al.

European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000; 76: 162–168.

23.

SmPC Aldara 5% cream.

24.

Patel

Yanofsky

Goldenberg

. Genital warts a comprehensive review. J Clin Aesthet Dermatol 2012; 5: 25–36.

25.

Meltzer

Monk

Tewari

. Green tea catechins for treatment of external genital warts. Am J Obstet Gynecol 2009; 200: 233.e1–233.e7.

26.

Vender

Bourcier

Bhatia

et al.

Therapeutic Options for external genital warts. J Cutan Med Surg 2013; 17: S61–S67.

27.

Werner

Westfechtel

Dressler

et al.

Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis. Sex Transm Infect 2017; 93: 155–161.

28.

Schäfer

Schnoor

. Medication-based self-treatment of condylomata acuminata (German). Der Deutsche Dermatol 2014; 62: 200–205.

29.

Juhl

Seferovic

Antonijevic

et al.

Combined treatment of anogenital HPV infection with cryodestruction, podophyllin 25% and post-ablation immunomodulation with sinecatechins 15% ointment – retrospective analysis. Int J STD AIDS 2016; 27: 1071–1078.

30.

Lacey

Goodall

Ragnarson Tennvall

et al.

Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003; 79: 270–275.

31.

Tatti

Swinehart

Thielert

et al.

Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 2008; 111: 1371–1379.

32.

Scheinfeld

Lehman

. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J 2006; 12: 5–5.

33.

Schöfer

Van Ophoven

Henke

et al.

Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. Eur J Dermatol 2006; 16: 642–648.

34.

Linkner

Haddican

et al.

A single-blinded randomized controlled study to assess the efficacy of twice daily application of sinecatechins 15% ointment when used sequentially with cryotherapy in the treatment of external genital warts. J Drugs Dermatol 2014; 13: 1400–1405.

35.

NHS Scotland Scottish Medical Consortium. Advice on camellia sinensis (green tea) leaf extract 10% ointment (Catephen®) SMC No. 1133/16), https://www.scottishmedicines.org.uk/SMC_Advice/Advice/1133_16_camellia_sinensis_green_tea_leaf_Catephen (2016, accessed 30 January 2017).

36.

All Wales Medicines Strategy Group Final Appraisal Recommendation Green tea leaf extract (Catephen®) 10% ointment, http://www.awmsg.org/awmsgonline/app/appraisalinfo/2739 (2016, accessed 30 January 2017).

37.

NICE External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment. Evidence summary: new medicine 2015, https://www.nice.org.uk/advice/esnm66/chapter/Key-points-from-the-evidence (2015, accessed 30 January 2017).

38.

Khan

Afaq

Saleem

et al.

Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006; 66: 2500–2505.

39.

Ahmad

Cheng

Mukhtar

. Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. Biochem Biophys Res Commun 2000; 257: 328–334.

40.

Yashiki

Sonoda

et al.

Green tea polyphenols induce apoptosis in vitro in peripheral blood T lymphocytes of adult T-cell leukemia patients. Jpn J Cancer Res 2000; 91: 34–40.

41.

Yang

Liao

Kim

et al.

Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 1998; 19: 611–616.

42.

Ahn

Yoo

Huh

et al.

Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev 2003; 12: 383–390.

43.

Beltz

Bayer

Moss

et al.

Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem 2006; 6: 389–406.

44.

Nguyen

Doan

Brunell

et al.

Apoptotic gene expression in sinecatechins-treated external genital and perianal warts. Viral Immunol 2014; 27: 556–558.

45.

Hemmi

Kaisho

Takeuchi

et al.

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196–200.

46.

Gibson

Lindh

Riter

et al.

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002; 218: 74–86.

47.

Weeks

Gibson

. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J Interferon Res 1994; 14: 81–85.

48.

Imbertson

Beaurline

Couture

et al.

Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998; 110: 734–739.

49.

Mashiah

Brenner

. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. Clin Exp Dermatol 2008; 33: 74–76.

50.

Edwards

Ferenczy

Eron

et al.

Self-administered topical 5% Imiquimod cream for external anogenital warts. Arch Dermatol 1998; 134: 25–30.

51.

Beutner

Tyring

Trofatter

Jr et al.

Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998; 42: 789–794.

52.

US Prescribing Information Zyclara cream, 3.75% dated August 2014.

53.

FDA Center for drug evaluation and research Medical Review NDA 201153 (Zyclara cream 3.75%), 2010.

54.

Patel

Yanofsky

Goldenberg

. Genital warts a comprehensive review. J Clin Aesthet Dermatol 2012; 5: 25–36.

55.

Tyring

. Sinecatechins Effects on HPV-induced enzymes involved in inflammatory mediator generation. J Clin Aesthet Dermatol 2012; 5: 19–26.

56.

Tatti

Stockfleth

Beutner

et al.

Polyphenon E: a new treatment for external anogenital warts. BJD 2010; 162: 176–184.

57.

SmPC Veregen 10% Ointment, Status of information September 2013, http://mri.medagencies.org/download/DE_H_1659_001_FinalPI.pdf (accessed 21 May 2017).

58.

Gross

Meyer

Pres

et al.

A randomized, double-blind, four-arm parallel-group, placebo-controlled phase II/III study to investigate the clinical efficacy of two galenic formulations of polyphenon E in the treatment of external genital warts. JEADV 2007; 21: 1404–1412.

59.

US Prescribing Information Veregen 15% dated November 2012.

60.

Beutner

Conant

Friedman-Kien

et al.

Patient-applied podofilox for treatment of genital warts. Lancet 1989; 1: 831–834.

61.

Kirby

Dunne

King

et al.

Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. Am J Med 1990; 88: 465–469.

62.

Van Krogh

Szpak

Andersson

et al.

Self-treatment using 0.25%–0.50% podophyllotoxin-ethanol solutions against penile condylomata acuminata: a placebo-controlled comparative study. Genitourin Med 1994; 70: 105–109.

63.

Stone

Becker

Hadgu

et al.

Treatment of external genital warts: a randomized clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. Genitourin Med 1990; 66: 16–19.

64.

Godley

Bradbeer

Gellan

et al.

Cryotherapy compared with trichloroacetic acid in treating genital warts. Genitourin Med 1987; 63: 390–392.

65.

Jensen

. Comparison of podophyllin application with simple surgical excision in clearance and recurrence of perianal condylomata acuminata. Lancet 1985; 2: 1146–1148.

66.

Khawaja

. Podophyllin versus scissor excision in the treatment of perianal condylomata acuminata: a prospective study. Br J Surg 1989; 76: 1067–1068.

67.

Liang

Tang

et al.

Evaluation of photodynamic therapy using topical aminolevulinic acid hydrochloride in the treatment of condylomata acuminata: a comparative, randomized clinical trial. Photodermatol Photoimmunol Photomed 2009; 25: 293–297.